Abcellera Biologics Inc (ABCL NASDAQ) stock market data APIs
$2.433
-0.07(-2.9%)
as of April 17, 2025
Abcellera Biologics Inc Financial Data Overview
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Prev. Close
2.433
Open
2.365
High
2.457
Low
2.3353
52 wk Range
1.8906-4.3398
Market Cap
721 M
Shares Outstanding
298 M
Revenue
28 833 K
EPS
-0.12
Beta
0.494
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Abcellera Biologics Inc data using free add-ons & libraries
Get Abcellera Biologics Inc Fundamental Data
Abcellera Biologics Inc Fundamental data includes:
- Net Revenue: 28 833 K
- EBITDA: -223 916 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-18
- EPS/Forecast: -0.1471
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Abcellera Biologics Inc News
New
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
Are you a successful asset manager who has already amassed more than $1 billion in personal wealth? If not, there are probably a few things you can learn from the small list of folks who have. Luckil...
Billionaire Investor Stan Druckenmiller and Insiders Are Piling Into These 11 Stocks
In this article, we will take a detailed look at Billionaire Investor Stan Druckenmiller and Insiders Are Piling Into These 11 Stocks. For a quick overview of such stocks, read our article Billionair...
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
VANCOUVER, British Columbia, March 11, 2024--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) and Biogen Inc. (Nasdaq: BIIB) have entered into a strategic collaboration to discover antibodies for a novel tar...
AbCellera Announces Resignation of Board Member
VANCOUVER, British Columbia, February 23, 2024--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company’s Boar...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
